SCHEMBL3525255

SCHEMBL3525255

COC(=O)CCc1cc2cc(Br)ccc2[nH]1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.54
MTNR1A P48039 4/20 0.48
MTNR1B P49286 3/20 0.48
FLT3 P36888 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.44
FFAR1 O14842 2/20 0.44
HRH4 Q9H3N8 1/20 0.43
HRH3 Q9Y5N1 1/20 0.43
HDAC3 O15379 1/20 0.42
HDAC4 P56524 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC7 Q8WUI4 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC10 Q969S8 1/20 0.42
HDAC11 Q96DB2 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
HDAC9 Q9UKV0 1/20 0.42
HDAC5 Q9UQL6 1/20 0.42
HPGD P15428 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31472119 0.86 FLT3 (0.50) EGFRMTNR1AMTNR1BFLT3SMN1; SMN2
SCHEMBL852679 0.84 BACE1 (0.49) EGFRMTNR1AMTNR1BFLT3SMN1; SMN2
SCHEMBL31561464 0.84 FFAR1 (0.54) FLT3FFAR1HDAC3HDAC4HDAC1
SCHEMBL22074027 0.83 MTNR1A (0.68) MTNR1AMTNR1BFLT3HRH3HDAC6
SCHEMBL3525308 0.83 MTNR1A (0.48) EGFRMTNR1AMTNR1BFLT3SMN1; SMN2
SCHEMBL3525492 0.82 MTNR1A (0.50) EGFRMTNR1AMTNR1BSMN1; SMN2HRH4
SCHEMBL9108723 0.81 MTNR1A (0.61) EGFRMTNR1AMTNR1BSMN1; SMN2HRH4
SCHEMBL3529064 0.80 HRH4 (0.46) EGFRMTNR1AMTNR1BSMN1; SMN2HRH4
SCHEMBL3528754 0.80 MTNR1A (0.45) EGFRMTNR1AMTNR1BSMN1; SMN2HPGD
SCHEMBL25432502 0.78 EGFR (0.49) EGFRMTNR1AMTNR1BSMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436040-B2 Method of treating conditions involving PPAR-receptors with indole compounds LABORATOIRES FOURNIER S.A. (FR) 2013-05-07 US disclosed
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds LABORATORIES FOURNIER S.A. (FR) 2010-11-11 US disclosed
US-7795297-B2 Indole compounds, method of preparing them and uses thereof LABORATORIES FOURNIER S.A. (FR) 2010-09-14 US disclosed
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LABORATOIRES FOURNIER S.A. (FR) 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LIPG, GPR119, IAPP EGFR 1560/4885MTNR1A 301/4885MTNR1B 164/4885
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds GPR119, PPARA, PPARG EGFR 456/4885MTNR1A 22/4885MTNR1B 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.